RegentAtlantic Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $19.3M | Sell |
440,788
-9,651
| -2% | -$469K | 0.58% | 25 |
|
|
2022
Q2 | $23.6M | Buy |
450,439
+3,632
| +0.8% | +$185K | 0.78% | 19 |
|
|
2022
Q1 | $23.1M | Sell |
446,807
-6,032
| -1% | -$313K | 0.65% | 25 |
|
|
2021
Q4 | $26.7M | Sell |
452,839
-9,789
| -2% | -$485K | 0.75% | 21 |
|
|
2021
Q3 | $19.9M | Buy |
462,628
+5,640
| +1% | +$250K | 0.6% | 27 |
|
|
2021
Q2 | $17.9M | Sell |
456,988
-3,246
| -0.7% | -$126K | 0.55% | 30 |
|
|
2021
Q1 | $16.7M | Sell |
460,234
-11,602
| -2% | -$412K | 0.56% | 30 |
|
|
2020
Q4 | $17.4M | Sell |
471,836
-28,701
| -6% | -$1.05M | 0.69% | 24 |
|
|
2020
Q3 | $17.4M | Buy |
500,537
+16,795
| +3% | +$589K | 0.78% | 24 |
|
|
2020
Q2 | $15M | Buy |
483,742
+7,889
| +2% | +$268K | 0.84% | 23 |
|
|
2020
Q1 | $14.7M | Sell |
475,853
-24,786
| -5% | -$845K | 1.15% | 16 |
|
|
2019
Q4 | $18.6M | Sell |
500,639
-5,566
| -1% | -$198K | 1.13% | 16 |
|
|
2019
Q3 | $17.3M | Sell |
506,205
-13,072
| -3% | -$475K | 1.14% | 14 |
|
|
2019
Q2 | $21.3M | Sell |
519,277
-10,595
| -2% | -$421K | 1.44% | 12 |
|
|
2019
Q1 | $21.4M | Sell |
529,872
-625
| -0.1% | -$25K | 1.49% | 12 |
|
|
2018
Q4 | $22M | Buy |
530,497
+46,978
| +10% | +$1.95M | 1.86% | 7 |
|
|
2018
Q3 | $20.2M | Buy |
483,519
+12,692
| +3% | +$489K | 1.55% | 7 |
|
|
2018
Q2 | $16.2M | Buy |
470,827
+19,628
| +4% | +$671K | 1.4% | 10 |
|
|
2018
Q1 | $15.2M | Buy |
451,199
+14,428
| +3% | +$496K | 1.27% | 10 |
|
|
2017
Q4 | $15M | Sell |
436,771
-4,929
| -1% | -$168K | 1.23% | 14 |
|
|
2017
Q3 | $15M | Sell |
441,700
-1,223
| -0.3% | -$39.3K | 1.3% | 10 |
|
|
2017
Q2 | $14.1M | Sell |
442,923
-8,453
| -2% | -$267K | 1.28% | 10 |
|
|
2017
Q1 | $14.7M | Sell |
451,376
-21,282
| -5% | -$671K | 1.36% | 8 |
|
|
2016
Q4 | $14.6M | Sell |
472,658
-20,228
| -4% | -$618K | 1.42% | 8 |
|
|
2016
Q3 | $15.8M | Sell |
492,886
-1,182
| -0.2% | -$39.5K | 1.64% | 7 |
|
|
2016
Q2 | $16.5M | Sell |
494,068
-17,204
| -3% | -$549K | 1.59% | 8 |
|
|
2016
Q1 | $14.4M | Sell |
511,272
-48,406
| -9% | -$1.38M | 1.58% | 9 |
|
|
2015
Q4 | $17.1M | Sell |
559,678
-6,132
| -1% | -$193K | 1.83% | 3 |
|
|
2015
Q3 | $16.9M | Buy |
565,810
+118
| +0% | +$3.78K | 1.62% | 6 |
|
|
2015
Q2 | $18M | Sell |
565,692
-3,910
| -0.7% | -$127K | 1.6% | 6 |
|
|
2015
Q1 | $18.8M | Sell |
569,602
-5,058
| -0.9% | -$161K | 1.65% | 6 |
|
|
2014
Q4 | $17M | Buy |
574,660
+22,779
| +4% | +$653K | 1.44% | 7 |
|
|
2014
Q3 | $15.5M | Sell |
551,881
-6,050
| -1% | -$170K | 1.45% | 9 |
|
|
2014
Q2 | $15.7M | Buy |
557,931
+16,719
| +3% | +$477K | 1.46% | 8 |
|
|
2014
Q1 | $16.5M | Buy |
541,212
+6,125
| +1% | +$183K | 1.61% | 6 |
|
|
2013
Q4 | $15.6M | Buy |
535,087
+24,838
| +5% | +$723K | 1.5% | 7 |
|
|
2013
Q3 | $13.9M | Buy |
510,249
+14,135
| +3% | +$385K | 1.52% | 6 |
|
|
2013
Q2 | $13.2M | Buy |
+496,114
| New | +$13.7M | 1.56% | 5 |
|
Other funds holding PFE
RegentAtlantic Capital's PFE Position: Q3 2022 in Review
RegentAtlantic Capital reduced its Pfizer (PFE) stake by 2.1% in Q3 2022, selling an estimated $469K and leaving 440,788 shares worth $19.3M. The position accounts for 0.58% of the portfolio, ranked #25.
RegentAtlantic Capital first reported a position in PFE in Q2 2013 and has held it in 38 quarters since. The position peaked at $26.7M in Q4 2021. 3,085 funds tracked by Wall St. Rank hold PFE as of Q3 2022.
- RegentAtlantic Capital held 440,788 shares of Pfizer worth $19.3M as of Q3 2022.
- RegentAtlantic Capital sold 9,651 Pfizer shares in Q3 2022, an estimated $469K.
- Pfizer made up 0.58% of RegentAtlantic Capital's portfolio in Q3 2022, its #25 holding.
- RegentAtlantic Capital first reported a position in Pfizer in Q2 2013 and has held it in 38 quarters since.
- RegentAtlantic Capital's Pfizer position peaked at $26.7M in Q4 2021.
- 3,085 funds tracked by Wall St. Rank held Pfizer as of Q3 2022.
Based on RegentAtlantic Capital's 13F filing for Q3 2022, filed 14 Nov 2022.